Masimo Earnings Call Transcripts
Fiscal Year 2026
-
Strong financial performance and margin expansion were achieved, with a clear strategy for 7%-10% annual growth through U.S. and international market share gains, advanced monitoring, and new product launches. AI-driven innovation and partnerships underpin a robust pipeline, while organizational momentum sets the stage for continued success.
Fiscal Year 2025
-
Management outlined a focused strategy on core healthcare markets, targeting 7%-10% annual revenue growth and 30% operating margin by 2028. Growth will be driven by U.S. and international share gains, advanced monitoring, and a robust innovation pipeline, with new AI-enabled sensors and platforms launching through 2028.
-
Q3 saw 8% revenue growth and 38% higher adjusted EPS, driven by strong demand, margin expansion, and operational improvements. Guidance was raised for both revenue and EPS, with a strong Q4 expected from consumables and contract execution.
-
Management outlined a vision to lead patient monitoring through AI, wearables, and commercial excellence, with major growth initiatives and new leadership in place. Financials remain strong, with recurring revenue, margin improvements, and robust contracting, while ongoing legal and partnership developments are expected to drive future value.
-
Q2 saw strong revenue and EPS growth, with significant margin expansion and effective cost controls. Updated 2025 guidance reflects higher EPS and reduced tariff impact, while leadership changes and innovation initiatives support long-term growth.
-
The company is refocusing on healthcare innovation after divesting its consumer business, driving growth through AI-enabled monitoring solutions and expanding in adjacent markets. Strong Q1 results, robust capital allocation plans, and operational resilience position it for continued leadership and double-digit growth potential.
-
Leadership is refocusing on core hospital monitoring, targeting 7%-10% growth and margin expansion. Q1 showed strong capital and consumable growth, with robust demand and margin improvement. Tariff mitigation, cost optimization, and ongoing litigation are key focus areas.
-
Q1 saw 10% revenue growth and 56% non-GAAP EPS growth, with strong healthcare performance and margin expansion. Guidance for 2025 remains robust despite new tariffs, and the divestiture of Sound United will fund share repurchases.
-
Growth targets for core and advanced products remain strong, with new hemodynamic and automation offerings supporting long-term expansion. Strategic partnerships and cost optimization drive margin improvements, while the consumer audio business divestiture is expected to fund debt repayment and share buybacks.
-
Management outlined a renewed focus on core healthcare, innovation, and operational efficiency, targeting 8%–11% revenue growth and significant margin expansion for 2025. Leadership changes have energized the workforce, while manufacturing shifts and project rationalization are driving improved profitability.
-
Management is refocusing on core healthcare markets, exiting non-core businesses, and driving innovation in patient monitoring and telehealth. Financial guidance for 2025 includes 8–11% healthcare revenue growth and a raised operating margin target of at least 26.5%.
Fiscal Year 2024
-
Q4 and full-year 2024 saw strong revenue and margin growth, driven by healthcare segment gains, cost optimization, and record new contracts. 2025 guidance projects 8–10% healthcare revenue growth and 22–29% non-GAAP EPS growth, with Sound United to be divested and excluded from results.
-
Leadership is driving a strategic refocus on core healthcare markets, divesting non-core assets, and streamlining the product pipeline. Margin expansion and 7-10% growth are targeted, with improved free cash flow and selective future M&A. Guidance and updates will be provided early next year.
-
Management outlined a strategy focused on core healthcare, platform-based innovation, and margin expansion. Growth is driven by recurring hospital contracts, new product launches, and increased revenue per driver, while divestiture of consumer assets and cost rationalization support profitability.
-
Management highlighted successful manufacturing shifts to Malaysia, ongoing strategic review of consumer business separation, and renewed focus on core healthcare growth. Margin expansion, cost reduction, and innovation are driving improved financial outlook, with recurring revenues supporting stability.
-
Q3 saw strong healthcare revenue growth and margin expansion, while non-healthcare remained weak. Strategic focus is on high-return projects, cost discipline, and a potential consumer business separation. 2024 guidance was raised, with healthcare margins expected to improve further in 2025.
-
Stable healthcare trends and strong contracting drive raised 2024 guidance, while consumer demand remains challenged. Strategic options for the consumer audio business are under review, with no set timeline. Margin expansion is expected from cost efficiencies and favorable product mix.
-
Healthcare revenues grew 23% year-over-year with record hospital conversions and improved gross margins, prompting raised full-year guidance. The company is advancing the separation of its consumer business, which could significantly boost operating margins and accelerate debt reduction.
-
Market share and patient volumes have rebounded, with stabilized inventory and strong product innovation. A potential JV or spin-off of the consumer business could eliminate debt and boost earnings, while new products and global telemonitoring expansion drive future growth.
-
Management outlined plans to separate the consumer business via sale or spin-off, aiming to accelerate margin expansion and focus on core healthcare growth. Margin targets are supported by manufacturing efficiencies and strong recurring revenue, while regulatory issues are being addressed with minimal expected impact.